Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Catalyst Pharmaceuticals, Inc. or Xenon Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Latest Biotechnology and Catalyst Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc. Stock News

As of March 11, 2026, Catalyst Pharmaceuticals, Inc. had a $3.0 billion market capitalization, compared to the Biotechnology median of $279.6 million. Catalyst Pharmaceuticals, Inc.’s stock is NA in 2026, NA in the previous five trading days and up 18.07% in the past year.

Currently, Catalyst Pharmaceuticals, Inc.’s price-earnings ratio is 14.5. Catalyst Pharmaceuticals, Inc.’s trailing 12-month revenue is $589.0 million with a 36.4% net profit margin. Year-over-year quarterly sales growth most recently was 7.6%. Analysts expect adjusted earnings to reach $2.852 per share for the current fiscal year. Catalyst Pharmaceuticals, Inc. does not currently pay a dividend.

Currently, Xenon Pharmaceuticals Inc. does not have a price-earnings ratio. Xenon Pharmaceuticals Inc.’s trailing 12-month revenue is $7.5 million with a % net profit margin. As of March 11, 2026, Xenon Pharmaceuticals Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.863 per share for the current fiscal year. Xenon Pharmaceuticals Inc. does not currently pay a dividend.

How We Compare Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.’s Quality Grades

Company	Ticker	Quality
Catalyst Pharmaceuticals, Inc.	CPRX	B
Xenon Pharmaceuticals Inc.	XENE	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Catalyst Pharmaceuticals, Inc. has a Quality Score of 77, which is Strong. Xenon Pharmaceuticals Inc. has a Quality Score of 30, which is Weak.

The Quality Grade Winner: Catalyst Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, Catalyst Pharmaceuticals, Inc. has a better overall quality grade than Xenon Pharmaceuticals Inc.. For investors who are looking for companies with higher quality than others in the same industry, Catalyst Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.’s Momentum Grades

Company	Ticker	Momentum
Catalyst Pharmaceuticals, Inc.	CPRX	B
Xenon Pharmaceuticals Inc.	XENE	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Catalyst Pharmaceuticals, Inc. has a Momentum Score of 61, which is Strong. Xenon Pharmaceuticals Inc. has a Momentum Score of 86, which is Very Strong.

The Momentum Grade Winner: Xenon Pharmaceuticals Inc.

As you can clearly see from the Momentum Grade breakdown above, Xenon Pharmaceuticals Inc. is considered to have stronger momentum compared to Catalyst Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Xenon Pharmaceuticals Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Catalyst Pharmaceuticals, Inc.	CPRX	B
Xenon Pharmaceuticals Inc.	XENE	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Catalyst Pharmaceuticals, Inc. has a Earnings Estimate Score of 75, which is Positive. Xenon Pharmaceuticals Inc. has a Earnings Estimate Score of 23, which is Negative.

The Earnings Estimate Revisions Grade Winner: Catalyst Pharmaceuticals, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Catalyst Pharmaceuticals, Inc. has a better Earnings Estimate Revisions Grade than Xenon Pharmaceuticals Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Catalyst Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. Grades

In addition to Quality, Momentum and Estimate Revisions, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Catalyst Pharmaceuticals, Inc. or Xenon Pharmaceuticals Inc. Stock?

Overall, Catalyst Pharmaceuticals, Inc. stock has a Momentum Score of 61, Estimate Revisions Score of 75 and Quality Score of 77.

Xenon Pharmaceuticals Inc. stock has a Momentum Score of 86, Estimate Revisions Score of 23 and Quality Score of 30.

Comparing Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.